Grant: Engage Grants Program
Université de Montréal
$25,000.00
New glutamate carboxypeptidase II ligands: novel drugs for neurological diseases, therapy and in vivo diagnostic of prostate cancer
EF 2010-11
Résumé
The glutamate carboxypeptidase II (GCPII) is a cell membrane-bound enzyme highly restricted to the brain, kidney tubules, the gastric and prostatic epithelium, overexpressed in prostate carcinoma. GCPII hydrolyses the substrate NAAG, a neuropeptide implicated in disorders that are thought to involve abnormalities in glutamatergic neurotransmission. In prostate cancer cells, the level of expression of GCPII follows the stage of the disease suggesting that it facilitates the development of cancer and metastatic process. There is significant interest in GCPII, as it is ideal for the development of specific targeted strategies, and offers opportunities for creating novel drugs for the clinical management of neurological diseases and the therapy or the in vivo diagnostic of prostate cancer.
The hypotheses we want to confirm in this projects are 1) the molecule we identified binds directly into or close to the catalytic site of GCPII, 2) it binds into a remote site which interferes with the output signal of the assay (allosteric effect), 3) it inhibits GCPII, directly or allosterically, and prevents the hydrolysis of NAAG and/or the binding of synthetic substrates, 4) it interferes with the binding of a yet unknown protein interacting with GCPII, 5) it will have a potential clinical impact on certain neurological diseases and diagnostic and treatment of prostate cancer and cancer in general.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
408098-2010
Name nom
Schmitzer, Andreea
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1202
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Physical sciences
Area of application fr
Sciences physiques
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
1
Nb partie
1
Application title
New glutamate carboxypeptidase II ligands: novel drugs for neurological diseases, therapy and in vivo diagnostic of prostate cancer
Keyword
NSERC
Application summary
The glutamate carboxypeptidase II (GCPII) is a cell membrane-bound enzyme highly restricted to the brain, kidney tubules, the gastric and prostatic epithelium, overexpressed in prostate carcinoma. GCPII hydrolyses the substrate NAAG, a neuropeptide implicated in disorders that are thought to involve abnormalities in glutamatergic neurotransmission. In prostate cancer cells, the level of expression of GCPII follows the stage of the disease suggesting that it facilitates the development of cancer and metastatic process. There is significant interest in GCPII, as it is ideal for the development of specific targeted strategies, and offers opportunities for creating novel drugs for the clinical management of neurological diseases and the therapy or the in vivo diagnostic of prostate cancer.
The hypotheses we want to confirm in this projects are 1) the molecule we identified binds directly into or close to the catalytic site of GCPII, 2) it binds into a remote site which interferes with the output signal of the assay (allosteric effect), 3) it inhibits GCPII, directly or allosterically, and prevents the hydrolysis of NAAG and/or the binding of synthetic substrates, 4) it interferes with the binding of a yet unknown protein interacting with GCPII, 5) it will have a potential clinical impact on certain neurological diseases and diagnostic and treatment of prostate cancer and cancer in general.